Inhibitors of DNMTs and HDACs can re-induce the expression of TSGs such as p16, RASSF1A, DAPK, and genes methylated in specific chemotherapeutic pathways.468 This “reprogramming” can enhance the sensitivity of tumor cells to cytotoxic agents. The gene discussed is CDKN2A; the disease is neoplasm.